Research Article| Volume 203, P61-65, August 2016

Autoimmune polyglandular syndrome type 3 (APS-3) among patients with premature ovarian insufficiency (POI)



      Autoimmune polyglandular syndrome type 3 – (APS-3), is defined as the coexistence of autoimmune thyroiditis with other non-ovarian autoimmune diseases without primary adrenal insufficiency. Additionally the definition of APS-3 also includes primary ovarian insufficiency (POI) coexistence with autoimmune thyroiditis.
      The main goal of that study is to assess the prevalence of APS-3 defined as coexistence of autoimmune thyroiditis with POI in population of 46 XX karyotype women with primary ovarian insufficiency (POI).
      The second goal is to investigate hormonal profile and insulin sensitivity in women with POI and subgroups of women with APS-3 – POI/APS-3(+) and without APS 3 – POI/APS-3(−).

      Materials and methods

      Anthropometric measurements, coexistence of autoimmune diseases, androgens, fasting glucose and insulin, glucose and insulin at 60′ and 120′ of oral glucose tolerance test (OGTT) and homeostasis model for insulin resistance (HOMA-IR), were determine in 98 patients aged between 18 and 39 with spontaneous 46 XX primary ovarian insufficiency (POI), in 33 POI/APS-3(+), 65 POI/APS-3(−), and 75 healthy controls.


      Continuous data were summarized by the mean ± standard deviation (SD), and categorical data by number (percentages). Data were checked for normality using Shapiro–Wilk test, the comparison between groups were performed using non-parametric Mann–Whitney or Kruskall–Wallis test. Pearson's correlation coefficient was used to assess the relationships between parameters. Statistical significance was defined as p values <0.05.
      Autoimmune thyroid disease (ATD) was presented in 33/98 (33.7%) patients with POI. The groups did not differ significantly in respect to age and body mass index (BMI). Women with POI, POI/APS-3(+) and POI/APS-3(−) showed significantly lower serum androgens in comparison to controls. Additionally women with POI/APS-3(+) showed hyperinsulinemia after 1 h of OGTT; No significant differences in serum fasting glucose, insulin and during 2 h OGTT between groups were observed.


      The prevalence of APS-3 is 33.7% in patients with spontaneous 46 XX primary ovarian insufficiency. Women with POI, POI/APS-3(+) and POI/APS-3(−) feature lower testosterone, androstendione, dehydroepiandrostendione sulphate in comparison to controls. Women with POI/APS-3(+) could have hyperinsulinemia and should be carefully evaluated for metabolic disorders.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Neufeld M.
        • Maclaren N.
        • Blizzard R.
        Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes.
        Medicine. 1980; 60: 35-62
        • Cutolo M.
        Autoimmune polyendocrine syndromes.
        Autoimmun Rev. 2014; 13: 85-89
        • Weetman A.
        Non-thyroid autoantibodies in autoimmune thyroid disease.
        Best Pract Res Clin Endocrinol Metab. 2005; 19: 17-32
        • Maclaren N.
        • Chen Q.Y.
        • Kukreja A.
        • Marker J.
        • Zhang C.H.
        • Sun Z.S.
        Autoimmune hypogonadism as part of an autoimmune polyglandular syndrome.
        J Soc Gynecol Investig. 2001; 8: 52-53
        • Nelson L.M.
        Clinical practice. Primary ovarian insufficiency.
        NEJM. 2009; 360: 606-614
        • Bachelot A.
        • Rouxel A.
        • Massin N.
        • et al.
        Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure.
        Eur J Endocrinol. 2009; 161: 179-187
        • Michalakis K.
        • Coppack S.W.
        Primary ovarian insufficiency: relation to changes in body composition and adiposity.
        Maturitas. 2012; 71: 320-325
        • Cooper A.R.
        • Baker V.L.
        • Sterling E.W.
        • Ryan M.E.
        • Woodruff T.K.
        • Nelson L.M.
        The time is now for a new approach to primary ovarian insufficiency.
        Fertil Steril. 2011; 95: 1890-1897
        • Betterle C.
        • Garelli S.
        • Coco G.
        • Burra P.
        A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3).
        Auto Immun Highlights. 2014; 11: 27-31
        • Eisenbarth G.S.
        • Gottlieb P.A.
        Autoimmune polyendocrine syndromes.
        N Engl J Med. 2004; 350: 2068-2079
        • Gardner D.G.
        • Shoback D.
        Greenspan's basic & clinical endocrinology.
        9th ed. The McGraw-Hill Companies, 2011
        • Ten S.
        • Maclaren N.
        Insulin resistance syndrome in children.
        J Clin Endocrinol Metab. 2004; 86: 2526-2539
        • Webber L.
        • Davies M.
        • Anderson R.
        • et al.
        ESHRE guideline: management of women with premature ovarian insufficiency.
        Hum Reprod. 2016; 31: 926-937
        • Panay N.
        • Kalu E.
        Management of premature ovarian failure.
        Best Pract Res Clin Obstet Gynaecol. 2009; 23: 129-140
        • Rajkiewicz M.
        • Szlendak-Sauer K.
        • Sulek A.
        • et al.
        A molecular and cytogenetic investigation of FMR1 gene prematutions in Polish patients with primary ovarian insufficiency.
        EJOG. 2011; 155: 176-179
        • Dragojevic-Dikic S.
        • MarisavIjevic D.
        • Mitrovic A.
        • Dikic A.
        An immunological insight into premature ovarian failure (POF).
        Autoimmun Rev. 2010; 9: 771-774
        • Ott J.
        • Pecnik P.
        • Promberger R.
        • Pils B.
        • et al.
        Dehydroepiandrostenadione in women with premature ovarian failure and Hashimoto's thyroiditis.
        Climacteric. 2014; 17: 92-96
        • Petrikova J.
        • Lazurova I.
        Ovarian failure and polycystic ovary syndrome.
        Autoimmun Rev. 2012; 11: 471-478
        • Persani L.
        • Hoek A.
        • Schoemaker J.
        • Drexhage H.A.
        Premature ovarian failure and ovarian autoimmunity.
        Endocr Rev. 1999; 18: 107-134
        • Nelson L.M.
        • Covington S.N.
        • Rebar R.
        An update: spontaneous premature ovarian failure is not an early menopause.
        Fertil Steril. 2005; 83: 1327-1332
        • Bakalov V.K.
        • Anastasi J.N.
        • Calis K.A.
        • et al.
        Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure.
        Fertil Steril. 2005; 84: 958
        • Betterle C.
        • Volpato M.
        • Rees
        • et al.
        Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune disease: markers of low progression to clinical Addison's disease.
        J Clin Endocrinol Metab. 1997; 82: 932-938
        • Mendoza N.
        • Julia D.
        • Galliano D.
        • et al.
        Spanish consensus on premature menopause.
        Maturitas. 2015; 80: 220-225
        • Luborsky J.
        Ovarian autoimmune disease and ovarian autoantibodies.
        J Women's Health Gender-Based Med. 2002; 11: 585-593
        • Novosad J.A.
        Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation.
        BMC Women's Health. 2003; 3: 2
        • De Vos M.
        • Devroey P.
        • Fauser B.C.
        Primary ovarian insufficiency.
        Lancet. 2010; 376: 911-921
        • Silva C.A.
        • Yamakami L.Y.S.
        • Aikawa N.E.
        • Araujo D.B.
        • Carvalho J.F.
        • Bonfá E.
        Autoimmune primary ovarian insufficiency.
        Autoimmun Rev. 2014; 13: 427-430
        • Benetti-Pinto C.L.
        • Bedone A.
        Evaluation of serum androgen levels in women with premature ovarian failure.
        Fertil Steril. 2005; 83: 508-510
        • Kalantaridou S.N.
        • Karim A.C.
        • Vanderhoof V.H.
        • et al.
        Testosterone deficiency in young women with 46, XX spontaneous premature ovarian failure.
        Fertil Steril. 2006; 86: 1475-1482
        • Ates S.
        • Yesil G.
        • Sevket O.
        • Molla T.
        • Yildiz S.
        Comparison of metabolic profile and abdominal fat distribution between karyotypically normal women with premature ovarian insufficiency and age matched controls.
        Maturitas. 2014; 79: 306-310